Valuation : Beta Bionics, Inc.

Market Cap 784M 674M 635M 579M 1.08B 74.58B 1.09B 7.53B 2.91B 37.99B 2.94B 2.88B 120B P/E 2026 *
-8.16x
P/E 2027 * -8.1x
Enterprise Value 650M 559M 527M 480M 898M 61.85B 901M 6.24B 2.41B 31.51B 2.44B 2.39B 99.83B EV / Sales 2026 *
4.86x
EV / Sales 2027 * 3.95x
Free-Float
98.89%
Yield 2026 *
-
Yield 2027 * -
1 day-1.44%
1 week-13.40%
Current month-13.53%
1 month+5.18%
3 months+25.73%
6 months+57.25%
Current year-43.39%
1 week 16.91
Extreme 16.9101
19.97
1 month 16.15
Extreme 16.15
20.74
Current year 8.8
Extreme 8.8
32.58
1 year 8.8
Extreme 8.8
32.71
3 years 8.8
Extreme 8.8
32.71
5 years 8.8
Extreme 8.8
32.71
10 years 8.8
Extreme 8.8
32.71
Manager TitleAgeSince
Chief Executive Officer 50 15/08/2022
Director of Finance/CFO 37 01/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 01/02/2020
Director/Board Member 50 15/08/2022
Director/Board Member 63 01/10/2024
Date Insider Type Main position Quantity % Market Cap. Importance
3/9/26 Sell

Chief Executive Officer

-5,641 0.0125%
2/9/26 Sell

Executive/Senior Manager

-4,375 0.0097%
2/9/26 Sell

Executive/Senior Manager

-5,327 0.0118%
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%-13.40%-30.64% - 784M
-0.41%-2.23%+26.88%+17.42% 224B
-1.30%-4.17%+5.01%-19.16% 144B
+2.01%-2.45%-19.82%+19.32% 125B
-1.92%-5.79%-57.97%-18.93% 65.16B
-0.56%-0.77%-20.24%-14.91% 50.05B
+0.46%-3.66%+10.49%+15.53% 49.67B
-1.18%-4.55%+15.34%+26.58% 40.81B
-0.95%-3.23%+36.57%+51.99% 39.77B
-0.52%-7.86%+113.88%+31.98% 30.96B
Average -0.58%-3.24%+7.95%+12.20% 76.99B
Weighted average by Cap. -0.35%-2.30%+7.25%+8.43%

Financials

2026 *2027 *
Net sales 134M 115M 108M 98.84M 185M 12.74B 186M 1.29B 497M 6.49B 503M 492M 20.56B 180M 155M 146M 133M 248M 17.1B 249M 1.73B 667M 8.71B 675M 660M 27.59B
Net income -94.91M -81.67M -76.9M -70.06M -131M -9.03B -132M -911M -352M -4.6B -356M -349M -14.58B -96.44M -82.98M -78.14M -71.2M -133M -9.18B -134M -926M -358M -4.67B -362M -354M -14.81B
Net Debt -134M -115M -108M -98.71M -185M -12.72B -185M -1.28B -496M -6.48B -502M -491M -20.53B -73.32M -63.09M -59.41M -54.13M -101M -6.98B -102M -704M -272M -3.55B -275M -269M -11.26B
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
422
Date Price Change Volume
11/09/26 USD 17.22 -1.15% 225,363
09/09/26 USD 17.42 -9.88% 848,749
08/09/26 USD 19.33 -0.46% 900,833
04/09/26 USD 19.42 -2.51% 1,407,468
03/09/26 USD 19.92 +2.60% 1,403,535
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
17.42USD
Average target price
20.31USD
Spread / Average Target
+16.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BBNX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!